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ABSTRACT
The product of varicella-zoster virus gene 62 (VZV
140k) Is the functional counterpart of the major
transcrlptional regulatory protein of herpes simplex
virus type 1 (HSV-1), ICP4. We have found that the
purified bacterlally expressed DNA binding domain of
VZV 140k (residues 417-647) Is a stable dimer In
solution. As demonstrated by the appearance of a novel
protein - DNA complex of intermediate mobility in gel
retardation assays, following In vitro co-translation of
a pair of differently sized VZV 140k DNA binding domain
peptides, the 140k DNA binding domain peptide binds
to DNA as a dimer. In addition, the DNA binding domain
peptide of HSV-1 ICP4 readily heterodimerizes with the
VZV 140k peptide on co-translation, Indicating that
HSV-1 ICP4 and VZV 140k possess very similar
dimerizatlon interfaces. It appears that only one fully
wild type subunit of the dimer is sufficient to mediate
sequence specific DNA recognition In certain
circumstances. Co-lmmunopreclpitation analysis of
mutant DNA binding domain peptides, co-translated
with an epitope-tagged ICP4 DNA binding domain,
shows that the sequence requirements for dimerlzation
are lower than those necessary for DNA binding.
INTRODUCTION
Varicella-zoster virus is the causative agent of chickenpox on
initial exposure and shingles on subsequent reactivation from
latency. It is a member of the neurotropic alphaherpesvirinae
subfamily and is genetically closely related to herpes simplex virus
type I (1,2). Studies on the mechanisms of gene regulation during
VZV infection are at an early stage, principally as a result of
the poor growth properties of VZV in tissue culture. Much of
our current understanding of alphaherpesvirus gene regulation
has been derived from the more intensively studied HSV-l
prototype system. To date, 75 HSV-1 transcription units have
been defined and are expressed in a complex temporally regulated
cascade. The HSV-1 genes can be divided into three broad classes
dependent on their kinetics of expression and the response to
inhibitors of macromolecular synthesis. These are classified as
immediate-early (IE), early and late (for reviews, see 3,4). On
HSV-1 infection, the first genes to be expressed in advance of
any viral protein synthesis are the five IE genes, the products
of at least three of which are involved in the transcriptional
regulation of the later classes of HSV-1 genes (5). The product
of the HSV-1 IE3 gene, ICP4, is essential for the activation of
early and late gene transcription (6—9) and is also required for
the autoregulation of its own promoter (10—12) and is therefore
considered to be the major transcriptional regulatory protein of
HSV-1.
Four varicella-zoster virus proteins have been detected in cells
infected in the presence of cycloheximide (13) and as such they
appear to be regulated in a fashion analogous to the HSV IE
genes. All four have sequence homologues among the HSV-1
IE proteins (1). The product of VZV gene 62 has a predicted
Mr of 140,000D (VZV 140k) and is the homologue of HSV-1
ICP4 on the basis of sequence homology and its position within
the viral genome. Moreover, there is firm evidence that the VZV
140k protein is the functional counterpart of HSV-1 ICP4, as
140k can complement HSV-1 mutants lacking functional ICP4
(14-16). In transient transfection assays, VZV 140k strongly
transactivates expression of VZV putative early and late gene
promoters, and selected heterologous viral and cellular promoters
(17-21). In transient tissue culture experiments, 140k either
negatively autoregulates or transactivates its own gene 62
promoter, depending on the cell type used (22,23). Although there
is no definite proof for an essential role of 140k in VZV biology,
the functional similarity to the indispensable ICP4 protein of
HSV-1 certainly argues for an important role in the VZV life
cycle.
The primary sequence of VZV 140k has been divided into five
regions on the basis of amino acid similarity to the homologous
HSV-1 ICP4 protein (24). Protein regions 2 and 4 are particularly
highly conserved and were predicted to have functional
importance. Indeed, mutations within these regions are deleterious
to the regulatory functions of HSV-1 ICP4. In particular, those
within region 2 affected DNA binding, transactivation and
promoter repression (25-27). Similarly, an insertion mutation
in region 2 of VZV 140k inhibits the transactivation and
repression phenotypes of 140k in transient transfection assays
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(22). The DNA binding domains of both the VZV 140k and the
HSV-1 ICP4 protein have been found to consist mainly of the
highly conserved region 2 sequences. Sequences spanning region
2 of each protein yield a stable, physically separable (28), DNA
binding domain when expressed in isolation in bacteria (29-32).
At least for ICP4, the isolated DNA binding domain has a DNA
binding specificity very similar to the intact protein (33). The
ICP4 protein recognizes a range of DNA binding sites, many
of which conform broadly to the consensus ATCGT-
CnnnnYCGRC (34). The 140k DNA binding domain is less
sequence specific than ICP4 and this low specificity of binding
allows the recognition of multiple sequences within target
promoters (32). Because an antigenic epitope spanning the
boundary between regions 1 and 2 is conserved in both VZV
140k and HSV-1 ICP4, it is likely that at least some similar
structural features are shared between the DNA binding domains
of the two proteins (35).
As is the case for many other DNA binding proteins, the native
form of the HSV-1 ICP4 protein is homodimeric (36,37) and
evidence suggests it binds to DNA as a multimer (38), and the
stoichiometry appeared to be two monomers per binding site (39).
In addition, the isolated ICP4 DNA binding domain peptide exists
as a stable dimer in solution (33), suggesting that sequences
overlapping the DNA binding domain are involved in the
dimerization of the intact ICP4 protein. Although the VZV 140k
protein appears to share many common features with its HSV-1
counterpart, numerous variations have been identified in the
details of their regulatory functions (21,22) and the DNA binding
characteristics of their isolated DNA binding domains (32). We
sought to establish whether the similarities between these two
proteins extended to their oligomeric state and the sequences
involved in the formation of possible higher order complexes.
In this study we report that the DNA binding domain of the
VZV 140k protein is a stable dimer in solution, and we
demonstrate that the 140k DNA binding domain interacts with
its DNA recognition sites as a dimer. In addition, we have
extended the similarities previously recognised between the VZV
140k and HSV-1 ICP4 proteins to include structural similarities;
the two proteins must have very similar dimerization interfaces
as heterodimer formation readily occurs between their
corresponding DNA binding domain peptides. Interestingly, these
heterodimers can interact with DNA sequences to which the
HSV-1 ICP4 DNA binding domain homodimers do not bind,
suggesting that only one fully wild type subunit of the dimer is
sufficient for specific DNA binding. Finally, we present data to
show that the dimerization activity of these homologous
alphaherpesvirus DNA binding domains has a lower protein
sequence requirement and is less mutation sensitive than the DNA
binding function.
MATERIALS AND METHODS
Plasmids and bacteria
Plasmid p585T7a is a T7 expression vector derived from pET-8c
(40), which includes a multiple cloning region preceded by an
ATG start codon (32). DNA fragments encompassing the highly
conserved region 2 (Fig. 1) of VZV gene 62 were inserted into
the p585T7a expression vector, as detailed below:
Expression plasmids p585T7aVT2 and p585T7aVT2X contain
the VZV gene 62 sequences encoding residues 417 — 647 as
described (32). The products of plasmids p585T7aVT2 and
p585T7aVT2X are referred to as VT2 (256 residues, Mr
-28.4kD) and VT2X (240 residues, Mr -26.7kD) respectively
(Fig. 1). Plasmid p585T7aVT4 was constructed by inserting the
BspHl-BamHl fragment of p585T7aVT2 (encompassing gene
62 codons 462-647) into the complementary Ncol and BamHl
sites of plasmid p585T7a. Plasmid p585T7aVT4X was derived
from p585T7aVT4 by insertion of an oligonucleotide, containing
stop codons in all three reading frames, into the BamHl site at
the 3' end of the VZV gene 62 coding sequences. The product
of p585T7aVT4X, termed VT4X (191 residues, Mr -21.2kD),
comprises an N-terminal vector-encoded methionine residue
preceding VZV 140k residues 462-647, followed by five C-
terminal residues (GDQLI) encoded by vector sequences 3' to
the insert. Plasmids expressing peptides VT5 and VTll were
constructed using appropriate restriction enzyme sites in the gene
62 sequences (32). Similarly, plasmids expressing the VT8 and
VT12 peptides included the EcoKl-Ncol fragment of plasmid
pC34 and the Rsal-Kpnl fragment of plasmid p585T7aVT2,
respectively, cloned into p585T7 expression vectors with an
appropriate linker to maintain the reading frame. The gene 62
coding regions included in each 140k DNA binding domain
deletion peptide are given in Figure 7A.
Plasmids pT7I9X and pT7I10X include sequences
encompassing the HSV-1 ICP4 DNA binding domain as
described (30). The products of plasmids pT7I9X and pT7I10X
are referred to as I9X and IIOX respectively (Fig. 1). Plasmids
pi 12—119 are derivatives of plasmid pi75 containing 4 codon
insertions into the ICP4 coding sequence as described (25). The
Nrul —BamHl fragments carrying the il2 to il9 insertion
mutations were isolated from plasmids pi 12-pi 19 and cloned
into the Nrul-BamHl sites of plasmid pJHOX (a p585T7a
derivative of pT7I10X). The resulting plasmids, pT7I10il2X-
il9X encoded insertion mutation versions of the II OX ICP4 DNA
binding domain (Fig. 6A).
Plasmid pNXHOX encodes a fusion protein comprising
residues 1-105 of HSV-1 ICP0, fused to the N-terminal end
of the IIOX peptide (Fig. 6A). It was constructed by ligating the
EcoRl —Pstl fragment of plasmid pJHOX (including ICP4 codons
275-523) to the Pstl-Xhol fragment (including ICP0 codons
1 -105) of plasmid pT7110 (41), with the aid of an Xhol-EcoM
adaptor which maintains the translational reading frame. The
product of plasmid pNXHOX is termed NXI10X; translation
begins at the first ATG of the HSV-1 IE1 gene, and a single
vector-encoded residue is at the C-terminal end of the NXI10X
fusion peptide (predicted size of 40kD).
All plasmids were constructed and maintained in E.coli strain
DH5a. Their authenticity was confirmed by extensive restriction
enzyme analysis and direct DNA sequencing. Plasmids were
transformed into E.coli strain BL21 (DE3) pLysS (40) for the
bacterial expression experiments.
Bacterial expression and purification of the VZV 140k DNA
binding domain
E.coli transformed with p585T7aVT2 were grown up, induced,
harvested and crude bacterial extracts prepared exactly as
described (32). The VZV 140k DNA binding domain was
purified from the initial 35% ammonium sulphate precipitated
extract by two steps of Pharmacia FPLC ion exchange
chromatography, followed by a gel filtration step. The following
buffer was used for all column elutions at the salt concentrations
specified: 50mM N-2-hydroxyethylpiperazine-N'-2-ethane-
sulfonic acid (HEPES) (pH 7.5), lmM phenylmethylsulfonyl
fluoride (PMSF), O.lmM dithiothreitol (DTT), 0.01%
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2-[(3-cholamidopropyl)-dimethylammonio]-l-propanesulfonate
(CHAPS). The first step used a 20ml Mono Q column
equilibrated in 0.1M NaCl buffer, lml of crude extract from a
one litre bacteria] culture was diluted to 5ml in 0.1M NaCl buffer
and loaded onto the column and eluted with a linear 0.1 to 1M
NaCl salt gradient. The VT2 peptide eluted in the flow-through.
Fractions containing VT2 were detected by Coomassie-staining
of SDS-polyacrylamide gels at this and subsequent stages of the
purification. Pooled Mono Q flow-through fractions were loaded
onto a 20ml Mono S column equilibrated in 0.25M NaCl buffer.
A 0.25M to 0.45M NaCl salt gradient eluted the VT2 peptide
at approximately 0.38M NaCl. Peak fractions were concentrated
by centrifugation in Centricon 10 filtration units (Amicon). 250/tl
of the concentrated VT2 sample was loaded onto a Superose 12
column equilibrated and eluted in O.38M NaCl buffer. VT2 eluted
in a single sharp peak and peak fractions were pooled and
concentrated to yield a preparation of VT2 of apparent
homogeneity on SDS PAGE gels. The preservation of DNA
binding activity was verified by gel retardation analysis of aliquots
of the VT2 peptide at each stage of the purification procedure
(data not shown).
Protein cross-linking
Incubation with glutaraldehyde is a standard method used to cross
link covalently aNH2 groups and the €-amino groups of lysine
residues of proteins in close proximity i.e. the monomers of an
oligomeric complex (42). 4/tg of either purified VT2 peptide or
bovine carbonic anhydrase (Sigma) was incubated in a buffer
containing 50mM HEPES (pH 7.5), 0.1M NaCl, lmM PMSF
either with or without 0.01 % glutaraldehyde for 30min at 31 °C.
The products of the cross-linking were analyzed by
electrophoresis through SDS-polyacrylamide gels using the
Biorad miniprotean II kit and visualised by staining with
Coomassie blue.
Gel Filtration chromatography
The dimerization of the 140k DNA binding domain was
determined by gel filtration analysis. A Pharmacia Superdex 75
column was equilibrated with elution buffer [50mM HEPES (pH
7.5), 0.3M NaCl, lmM PMSF, O.lmM DTT, 0.01% CHAPS]
before loading either purified VT2 or gel filtration protein
standards (Sigma) diluted to 200/xl in the elution buffer. The
eluted proteins were detected by the uv monitor and the identity
of the protein peaks verified by SDS PAGE. The retention volume
of each protein peak was provided by the softare in the FPLC
equipment.
In vitro coupled transcription/translation
The isolated HSV-1 ICP4 and VZV 140k DNA binding domains
were transcribed and translated in vitro (TNT, Promega) in the
presence of 35S-methionine, following the manufacturer's
instructions. T7 expression plasmids (described above) were
transcribed and translated by TNT rabbit reticulocyte lysates
either individually or in pairs. For co-translation experiments,
the amount of each plasmid required to yield equivalent amounts
of peptide was determined empirically. Typically, 0.012/tg of
plasmid p585T7aVT2X was used, as this yielded high levels of
VT2X expression whilst minimising VT2X binding to the input
plasmid DNA. Co-translation experiments contained half the
amount of each plasmid used in the single translation experiments.
Control translation reactions contained plasmid p585T7a. Within
each set of experiments, the total amount of input plasmid DNA
was equalised with plasmid p585T7a. Translation reactions were
incubated at 30°C for 90min. The translation products (1/tl) were
analysed by SDS PAGE and processed for autoradiography. In
vitro translation reactions for co-immunoprecipitation analysis
included 1/tg of each plasmid DNA.
DNA fragment probes
End-labelled probes for gel retardation analysis were prepared
as follows: The HSV-1 IE3 probe [including the strong consensus
ICP4 binding site spanning the mRNA start site (43), which is
also recognised by the 140k DNA binding domain peptides (32)]
included IE3 sequences —18 to +27 and was isolated as an
EcoRl-HindiH fragment from plasmid pUCIE3. Plasmid
pUCIE3 has the Aval(end filled)-BamHl fragment of the IE3
gene inserted between the HincU and BamHl sites of the PUC 19
multiple cloning region. The pUCIE3 HindlU-EcoRl fragment
was end-labelled with Klenow DNA polymerase and the probe
eluted from an 8% acrylamide gel and purified by ethanol
precipitation. The BT fragment probe (encompassing sequences
-130 to +57 of the VZV gene 62 promoter which include
numerous binding sites recognised by the 140k DNA binding
domain) was prepared as described (32).
Gel retardation assay
Appropriate amounts of extracts were incubated on ice with 1 ng
of a DNA probe in buffer giving final concentrations of lOmM
Tris.HCl (pH 8.0), O.lmM EDTA, lOOmM NaCl, 0.2%
CHAPS, 5mM DTT. After 20min, 0.2 volumes of loading buffer
[lOmM Tris-HCl (pH 8.0), lmM EDTA, lOmM
2-mercaptoethanol (BME), 0.1% CHAPS, 50% glycerol and
0.25mg/ml bromophenol blue] was added. Samples were applied
to a non-denaturing 4% polyacrylamide gel with 0.5XTBE
running buffer and run at 150V at 4°C for 3hr. Due to the
relatively small difference between the sizes of peptides VT2X
and VT4X, samples from the VT2X/VT4X co-translation
experiments were applied to 35cm gels and run for 40hr.
Protein —DNA complexes were detected by autoradiography of
dried gels.
Co-immunoprecipitation of in vitro translated proteins
DNA binding domain peptides were co-immunoprecipitated after
co-translation in vitro with fusion peptide NXI10X, which
includes an HSV-1 ICP0 epitope recognised by MAb 11,060
(44,45). TNT translation reactions (50/il) were pre-cleared by
incubation for 30min at 4°C with lOvol IP buffer (0.05M
Tris-HCl (pH7.5), 0.3M NaCl2, lmM EDTA, 0.2% NP40)
containing 5^ 1 normal mouse serum, 12.5/zl sheep anti-mouse
Ig (SaM) and 60/d 50% slurry of protein A sepharose beads.
After a 2min spin, 20/xl of the supernatant was incubated for 2hr
at 4°C with 2/*l MAb, 5/tl SaM, 60/xl 50% slurry protein A
sepharose, in a volume made up to 400/*1 with IP buffer. Immune
complexes were pelleted by centrifugation for 2min. The pellet
was washed 3 times with IP buffer, and then washed with a buffer
containing 0.6M LiCl, 0.1M Tris- HC1 (pH 7.5), 1 % BME. The
pellet was finally washed in PBSA and resuspended in 20/*l of
a denaturing boiling mix and heated at 100°C for 5min. The beads
were pelleted and the supernatant analysed by 12.5% SDS PA-
GE. After electrophoresis, the proteins were electroblotted to
nitrocellulose membranes. Co-immunoprecipitated 35S labelled
proteins were detected by autoradiography, or phosphorimaging
of the dried membranes using ImageQuant software (Molecular
Dynamics). Protease inhibitors (Boeringer Mannheim) were
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included throughout the procedure (bestatin, leupeptin, aprotinin,
PMSF, at concentrations recommended by the manufacturer).
RESULTS
Bacterial expression and purification of the VZV 140k DNA
binding domain peptide
The sequences of the VZV 140k polypeptide that are required
for the DNA binding have been mapped to between residues 417
and 647 (32), which encompasses the whole of the highly
VZV 140k
I I \
1 461 641 735
I I II VT2<X)
417 647
0 1 VT4X
4*2 647
HSV-1 1CP4
J J_
.us 4m
nox
Figure 1. VZV 140kandHSV-l ICP4 and their DNA binding domain peptides.
Regions 2 and 4 are highly conserved (46% and 56% identity respectively) between
the two proteins and are shown shaded, amino acid coordinates of the boundaries
of the conserved regions are given (inclusively) (24). Regions 1, 3 and 5 are
less highly conserved (15-25% identity). The VT2(X) and VT4X peptides
encompass the 140k DNA binding domain and the equivalent 19X and I10X
peptides (32) encompass the ICP4 DNA binding domain, the protein coding regions
included in each peptide are indicated (inclusively).
conserved region 2 and the C-terminal end of the relatively non-
conserved region 1 of the protein. The cloning and expression
of residues 417-647 of the VZV 140k coding region in E.coli
using the T7 system has been described (32) and the resultant
28.4kD peptide is referred to as VT2 (Fig. 1). Another VZV
140k peptide essentially comprising region 2 (peptide VT4X—
residues 462-647, Fig. 1), possesses a similar DNA binding
affinity to the larger VT2 peptide as determined by gel retardation
analysis, although VT4X fails to give a DNase I footprint (32).
We chose to purify the VT2 peptide as we considered it more
likely to reflect the characteristics of intact VZV 140k. VT2 was
purified by ion-exchange and gel filtration chromatography to
near homogeneity as described in the materials and methods
section, obtaining yields of at least lOmg per litre of bacterial
culture. Figure 2, track 1 shows an example of the Coomassie-
stained final preparation of purified VT2.
VT2
—
—
-44-1
' { 1
1
—
r
—
0.01% glutaraldehyde
1
 VI7 con TO con MW
kD
66
VT2 dimer I
VT2 monomer I
20.1
14.2
0 2 4 ft S
3
!•• Jr column retention
volume (ml)
97.4 45 |
66 29
molecular weight
protein standards (kD)
Figure 2. Glutaraldehyde cross-linking of the VZV 140k DNA binding domain
12.5% SDS PAGE analysis of samples of purified VT2 peptide incubated with
or without glutaraldehyde (see Materials and Methods). Tracks 2 and 4 contain
an equivalent amount of the monomeric carbonic anhydrase protein (Mr -29kD).
Track 5 contains molecular weight markers: BSA, 66kD; albumin, 45kD:
glyceraldehyde-3-phosphate dehydrogenase, 36kD; carbonic anhydrase 29kD;
trypsinogen, 24kD; trypsin inhibitor, 20. lkD; lactalbumin, 14.2kD. The positions
of VT2 monomer and dimer bands are indicated (calculated monomenc size,
28.4kD).
Figure 3. Gel filtration analysis of the VZV 140k DNA binding domain. The
uv trace shows a Superdex 75 column elution of a purified sample of the VT2
peptide (see Materials and Methods). The scale indicates retention volumes
corresponding to the uv trace. VT2 eluted with a retention volume of 9.3ml,
retention volumes of gel filtration protein standards are also indicated:
phosphorylase b, 97.4kD: BSA. 66kD: albumin. 45kD; carbonic anhydrase. 29kD.
The native size of approximately 65kD for the VT2 peptide (prediaed monomer
size, 28.4kD) was derived from a calibration curve plotted for a wide range of
protein standards (not shown).
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The purified VZV 140k DNA binding domain is a dimer in
solution
The native form of the intact HSV-1ICP4 protein is dimeric (37),
as is the isolated ICP4 DNA binding domain (33). By analogy,
it seemed probable that the VT2 peptide would also be dimeric.
To investigate this possibility, we incubated the purified VT2
peptide with the cross-linking agent glutaraldehyde and analysed
the products by SDS PAGE. Figure 2, track 3 shows clear
formation of VT2 dimers, not produced in the absence of
glutaraldehyde (Fig. 2, track 1). The faint VT2 products of higher
molecular weight than the dimers, which arise following
incubation with glutaraldehyde, presumably reflect either non-
specific cross-linking or a low level of higher order oligomers
in the VT2 sample.
Having found that the 140k DNA binding domain has the ability
to dimerize, we were interested to determine whether VT2 is
a stable dimer in solution, or whether an equilibrium exists
between VT2 monomers and dimers. An analytical gel filtration
FPLC column (Superdex 75, Pharmacia) was equilibrated in a
suitable buffer (see Materials and Methods) and the retention
volumes of a range of protein standards of known molecular
weights were determined. The purified VT2 peptide yielded a
sharp peak having a retention volume consistent with it being
a dimer in solution (Fig. 3). The failure to observe any peaks
eluting at the VT2 monomer position suggested that VT2 dimers
are not in equilibrium with monomers. Thus, the dimers appeared
to be highly stable units. The dimeric nature of VT2 was verified
using glycerol gradient centrifugation analysis to compare the
sedimentation rates of purified VT2 with those of protein
standards of known molecular weights loaded on the same
«#
-VT2X/ VT2X
tVT2X/VT4X
UVT4X/VT4X
gradients (data not shown). From these data, it was apparent that
the 140k DNA binding domain contains a dimerization surface
and it is likely that the intact 140k protein is also dimeric. Whether
the DNA binding domain region alone is sufficient for
dimerization of the intact protein, or whether other protein
sequences are additionally involved, remains to be determined.
The 140k DNA binding domain interacts with its DNA
recognition sites as a dimer
We used the method introduced by Hope and Struhl (46) to test
whether the 140k DNA binding domain peptide bound to its DNA
recognition site in an oligomerized form. The radiolabelled
peptides used for these analyses were produced by in vitro coupled
transcription/translation reactions in rabbit reticulocyte lysates
(see Materials and Methods). In vitro expression utilized the same
T7 expression plasmids used previously for the bacterial
expression (32) and the translation products were resolved by
gel retardation analysis using the BT probe fragment derived from
the VZV gene 62 promoter. The VT4X peptide, a DNA binding
competent truncated version of VT2 (Fig. 1), was tested for its
ability to from heterodimers in gel retardation assays with the
larger VT2X peptide (the VT2X peptide contains the same 140k
residues as VT2, but is more stable than the VT2 version) (32).
When the VT2X peptide was incubated with the DNA fragment,
it produced a slower-migrating species than did the VT4X
truncation peptide in gel retardation analysis (Fig. 4A). When
the two separately translated proteins were incubated together
only two bands corresponding to the separate VT2X and VT4X
protein —DNA complexes were observed. However, when the
two proteins were co-translated, a third intermediate band was
B
VT4X / VT4X
Figure 4. Gel retardation analysis of heterodimer formation. DNA probes were incubated with l/il (unless otherwise stated) of the in \>iiro translated extracts indicated
above each track (see Materials and Methods). Control translation reactions included plasmid p585T7a. Incubations for the tracks labelled 'co.' contained 2/d of
co-translation extracts. Incubations for tracks labelled 'mixed' contain lml of each separately translated extract. A. Heterodimer formation between the 140k peptides
VT2X and VT4X on the BT probe. B. Heterodimer formation between the VZV 140k peptide VT4X and the HSV-1 ICP4 peptide I9X on the IE3 probe. The
protein regions included in each peptide are illustrated in Fig. 1. Dimer complexes are identified on the right of each panel. Faint non-specific bands due to TNT
lysate proteins remain unlabelled.
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- * • I9X homodimer
- * • heterodimer
- * • VT4X homodimer
HSV-1 IE3
promoter probe
heterodimer
VT4X homodimer
VZV gene 62
promoter probe
Figure 5. Gel retardation analysis of VZV 14Ok/HSV-1 ICP4 peptide heterodimers.
Aliquots of extracts produced from a single set of in \itro translation reactions
(as identified above the tracks) were incubated with either the IE3 probe (top)
or the BT probe (bottom) The volumes of extracts used in the incubations were
as described in the legend of Figure 4. The details of the VT4X, I9X and U0U2X
peptides are given in Figs. 1 and 6A. Dimer complexes are identified on the
right.
observed (Fig. 4A, 'VT2X + VT4X co." track). We interpret
this intermediate band to correspond to a heterodimer formed
between the VT2X peptide and the smaller VT4X truncation
peptide. The finding that the intermediate heterodimeric
VT2X/VT4X band was not formed by mixing of the two peptides
confirms that the dimers are highly stable, as there is no detectable
exchange of monomer subunits within the 20 minute incubation
period of the binding reaction.
The VZV 140k DNA binding domain heterodimerizes with
the corresponding domain of HSV-1 ICP4
Given that the DNA binding domains of the VZV 140k and the
HSV-1 ICP4 proteins are both dimeric and that their primary
sequences are similar (Fig. 1), we thought it possible that they
might dimerize in a similar manner. Therefore we investigated
whether heterodimers could be produced between the HSV-1
ICP4 and VZV 140k DNA binding domains, using in vitro co-
translation of peptide VT4X with the larger HSV-1 ICP4 peptide,
I9X (Fig. 1) (30). The resulting DNA binding competent protein
complexes were resolved by gel retardation analysis, using the
HSV-1 IE3 probe, which is strongly recognised by both the VZV
140k and the HSV-1 ICP4 DNA binding domains (32). Figure
4B illustrates that a novel heterodimer band of intermediate
A
nox
NXIIOX
B
il2 il.3lil5 ilG il7 i!8 i l t
T I M T V T T
523a
Zl
* * * * * * * *
/ / * / / / / / ggSSS8SS
^ ^ ^
NXIIOX T -nrMi
1 2 3 4 5 6 7 B 9 10 1112 13 14 15 16 17 18 I t 20
Figure 6. Co-immunoprecipitation analysis of the insertion mutation versions of
the HSV-1 ICP4 DNA binding domain. A. Representations of the I10X peptide
and its epitope-tagged derivative. NXIIOX. The highly conserved ICP4 region
2 is indicated by light shading, the HSV-1 ICPO sequences are indicated by dark
shading. The arrows indicate the positions of the 4 amino acid insertions (25)
introduced into the following ICP4 codons: insertion i 12 at codon 310; i 13 at
324; il4 at 329: il5 at 337. il6 at 373; il7 at 398, il8 at 438; il9 at 494. B.
Pre-cleared in \vro translated extracts of the II OX insertion peptides and the
NXIIOX peptide. The I10il2X-U0il9X peptides were in \itro translated
individually, or co-translated with NXIIOX. followed by 'pre-cleanng' to reduce
background (see Materials and Methods). 20/tl aliquots of pre-cleared extracts
(as indicated above each track) were analysed by 12.5% SDS PAGE, 'con"
indicates an unprogrammed translation reaction. "MW indicates I4C
radiolabelled molecular weight markers: phosphorylase b. 97kD. bovine serum
albumin, 69kD; ovalbumin, 46kD; carbonic anhydrase, 30kD. The positions of
peptides NXIIOX (40kD) and I10X (28.2kD) are indicated on the left. The highly
acidic nature of the ICPO sequences reduced the mobility of the NXIIOX peptide.
C. Co-immunoprecipitatton analysis of the I10X insemon peptides. The pre-cleared
extracts shown in panel B were immunoprecipitated with MAb 11.060. * with
the exception of track 2 which included MAb 10.503 as a negative control (44)
Peptides included in the immunoprecipitation reactions were either co-translated
or mixed after translation. Molecular weight markers are as above.
mobility was clearly produced upon co-translation of VT4X and
I9X, and the relative amounts of the three complexes are in the
expected 1:2:1 proportions. The VT4X/I9X heterodimer was not
formed when the separately translated peptides were mixed after
translation. This result suggests that the VZV 140k and HSV-1
ICP4 proteins have very similar structural requirements, and
perhaps similar sequence requirements, for dimerization.
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Figure 7. Co-immunoprecipitation analysis of the VZV 140k DNA binding domain deletion peptides. A. Schematic of the region spanning the DNA binding domain
of the VZV 140k procein, the highly conserved region 2 is indicated by shading. Beneath, horizontal lines represent the 140k DNA binding domain deletion peptides
of the VT series (32), the 140k amino acid residues included in each are given. The VT peptides were in vitro translated individually, or co-translated with the
epitope-tagged NXIlOX peptide. The extracts were pre-cleared (panel B) and lmmunoprecipitated (panel Q as described in Figure 6. The relative positions of in
vitro translated peptides are indicated on the far left. The greater amount of NXIlOX peptkle in tracks 3 - 8 compared to tracks 9-14, panel C, is a direct consequence
of the high amount of NXIlOX in track 1. panel B. Instability of the NXIlOX fusion peptide is apparent following long exposure of the filter, as shown in lower
part of panel C. 'MW' indicates I4C radiolabelled molecular weight markers: myosin, 200kD; phosphorylase b, 97kD; bovine serum albumin. 69kD: ovalbumin.
46kD; carbonic anhydrase, 30kD; trypsin inhibitor, 21.5kD; lysozyme, 14.3kD.
Selected heterodimers with only one fully wild type subunit
can bind to DNA
The HSV-1 ICP4 protein DNA binding domain has a very low
affinity for the 140k binding sites in the VZV gene 62 promoter
(compared to its affinity for the IE3 probe) whereas the 140k
peptide recognizes sites in the VZV gene 62 promoter and also
the HSV-1 IE3 consensus binding site (32). In order to see
whether both subunits of the dimer contribute to the sequence
specificity of DNA binding, we tested whether in vitro produced
heterodimers of the ICP4/140k DNA binding domains were able
to recognise the VZV gene 62 promoter probe in gel retardation
analysis. The top panel of Figure 5 confirms the result of Figure
4B and shows that both homodimers and the heterodimer bind
to the IE3 probe. Aliquots of the same in vitro produced extracts
were tested for DNA binding activities on the VZV gene 62
promoter fragment probe (Fig. 5, bottom panel). The very low
affinity of the ICP4 DNA binding domain for this particular probe
is seen by the lack of any specific bands in the I9X track.
However the heterodimer clearly recognizes the gene 62 promoter
binding sites, as a band in a position consistent with the production
of a heterodimer-DNA complex (compare with top panel of Fig.
5) is formed upon co-translation of I9X and VT4X. This result
suggests that the specific interaction of the single VT4X monomer
with its DNA recognition site is sufficient to mediate the DNA
binding activity of the I9X/VT4X heterodimer. However, it is
also possible that the interaction with VT4X induces a
conformational change in the I9X subunit which allows interaction
with normally unrecognised binding sites (see discussion).
We were interested to distinguish sequences within the DNA
binding domain which specify dimerization and DNA recognition.
The functional domains of the ICP4 protein were originally
mapped by an insertion mutagenesis of the entire ICP4 coding
region (25-27). Many of the insertions within the DNA binding
domain prevented DNA binding of the intact ICP4 protein. It
is possible that some of these mutations affect DNA binding
indirectly, by interfering with dimerization. The VT4X/I9X
heterodimer experiment suggests that, in certain circumstances,
the specific DNA binding property of the heterodimer can be
provided by the VT4X subunit alone. Therefore it is possible
that VT4X heterodimers with altered forms of the I9X subunit
might also bind to DNA. Such DNA binding competent mutant
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Figure 8. Models for DNA recognition by the ICP4/140k dimers. Each oval
represents a DNA binding domain monomer. Each panel illustrates a possible
mode of binding site recognition as discussed in the text, and the binding sequence
represents the consensus ICP4 binding site where n = any nucleotide, Y =
pyrimidine, R = purine (34). The dimer represented comprises a wild type
monomer and a DNA binding compromised monomer (i.e. a monomer that has
a low binding affinity for the binding site, or containing a mutation that is
deleterious for DNA binding). A. Only one subunit of the dimer recognizes the
ICP4 consensus binding site. B. Binding of one monomer facilitates binding of
the second monomer. C. Heterodimerization induces a conformational change
in the DNA binding compromised monomer, such that it adopts a wild type
conformation that enables recognition of the binding site
heterodimers would identify positions which are involved in DNA
binding rather than dimerization. Therefore, insertion mutation
versions of the isolated ICP4 DNA binding domain (11 OX) were
in vitro co-translated with the VZV 140k DNA binding domain
peptide (VT4X) and heterodimer formation assayed by gel
retardation analysis.
The i 12 insertion into codon 310 in the CHerminal end of region
1 of ICP4 (Fig. 6A) greatly reduces the DNA binding activity
of the intact ICP4 protein (26). In accordance, we found that
an isolated ICP4 DNA binding domain including the i 12 insertion
(peptide I10H2X), produced no apparent band on either of the
DNA probe fragments used in Figure 5. However, the
I10il2X/VT4X heterodimers formed complexes with both the
HSV-1 IE3 and the VZV gene 62 promoter probes, with
intensities comparable to those formed by the VT4X homodimers.
This result is consistent with the idea that in certain circumstances
only one fully wild type monomer of the dimer is required for
the interaction with DNA in a specific manner. Additionally, a
previous study found that insertions at ICP4 residues 320 and
338 prevented DNA binding of the homodimer, but did not affect
dimerization of the intact ICP4 protein (47). These data suggest
that the C-terminal portion of region 1 and the N-terminal portion
of region 2 are important for the DNA binding function rather
than for dimerization.
II OX peptides containing insertion mutations at the majority
of positions throughout ICP4 region 2 ( i l4 - i l8 , see Fig. 6A),
failed to bind to DNA as either II OX homodimers or as
I10X/VT4X heterodimers (data not shown). However the simple
interpretation that these insertions disrupt dimerization is
arguable, as they may disrupt monomer interactions indirectly
or inhibit DNA binding of the heterodimers, via gross
conformational effects.
Insertions throughout the HSV-1 ICP4 DNA binding domain
that disrupt DNA binding do not prevent dimerization
A major limitation of assaying heterodimer formation by gel
retardation analysis is that only DNA binding competent
heterodimers are detected. Mutational analyses indicate that ICP4
DNA binding activity is highly sensitive to minor alterations of
the primary sequence (26,27). Therefore it is possible that some
heterodimers which include a truncated or mutated monomer,
fail to bind to DNA. Therefore the approach of co-
immunoprecipitation of heterodimers was adopted to determine
more stringently the effect of each insertion mutation on
dimerization. Sequences spanning a heterologous epitope were
fused to the ICP4 DNA binding domain, as described in the
Materials and Methods section. The epitope, from the N-terminus
of the HSV-1 ICPO protein, is recognised very efficiently by
monoclonal antibody 11,060 (44,45). The epitope-tagged ICP4
DNA binding domain is referred to as NXI10X (Fig. 6A).
Having established that the wild type 110X ICP4 DNA binding
domain could heterodimerize with the NXI10X domain following
in vitro co-translation, as determined by co-immunoprecipitation
assay (not shown), the analysis was repeated with each insertion
mutation version of the I10X domain. The insertions had no
apparent effect on peptide solubility, as all remained in the soluble
fraction after pre-clearing of the in vitro translated extracts (Fig.
6B). None of the insertions prevented dimerization with the
epitope-tagged domain, as all were co-immunoprecipitated by
MAb 11,060 (tracks 11-18, Fig. 6C). Additionally, the
interaction was a consequence of specific heterodimerization as
none of the insertion mutation peptides were co-immunoprecipi-
tated when mixed with NXI10X after translation (tracks 3-10,
Fig. 6C). It is apparent that DNA binding is more mutation
sensitive than dimerization, as many of the insertions disrupted
DNA binding (26, and see above).
Deletion of either the N- or the C-terminus of VZV 140k
region 2 disrupts dimerization
Having found that the HSV-1 ICP4 and VZV 140k DNA binding
domain peptides could readily heterodimerize, the co-
immunoprecipitation approach was adopted using a panel of VZV
140k DNA binding domain deletion mutants. These peptides have
sequential deletions into either the N- or C-terminus (Fig. 7A),
deletions significantly encroaching on either end of region 2
(VT8, VT11, VT12) failed to form DNA binding competent
heterodimers with an intact VT4X monomer (data not shown).
The epitope-tagged HSV-1 ICP4 DNA binding domain peptide,
NXI10X, was in vitro co-translated with each 140k deletion
peptide and co-immunoprecipitations were performed on the pre-
cleared in vitro translation extracts (Fig. 7B and C). The 140k
DNA binding domain peptides VT2X, VT4X and VT5
specifically and strongly heterodimerized with the epitope-tagged
domain (Fig. 7C, tracks 9-11). The VT2X peptide was also
specifically co-immunoprecipitated in the presence of 1M NaCl
(not shown), indicating that the interaction is not mediated by
DNA and is highly stable. Peptides VT11 and VT12 (Fig. 7A),
which have deletions into the N-terminal end of the 140k DNA
binding domain, also heterodimerized (Fig. 7C, tracks 13 and
14), although at a lower efficiency than the VT2X peptide.
Therefore, residues 504-647 (VT11) appear to be sufficient for
dimerization, while truncation of the domain to residues 526-647
(peptide VT12) reduced dimerization activity yet further.
Quantitation of the data found that VT11 and VT12
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heterodimerized with the epitope-tagged domain at efficiencies
of 15.3% and 5.7% (respectively) of that of VT2X. Co-
immunoprecipitation of peptide VT8, which has a deletion into
the C-terminal end of the VZV 140k DNA binding domain (Fig.
7A), was undetected even after prolonged exposures. We
conclude that the N-terminal portion of VZV 140k region 2
(between residues 472 and 526) contributes to normal
dimerization of the DNA binding domain whereas sequences in
the C-terminal portion (between residues 588 and 647) are
essential.
DISCUSSION
The results presented in this paper show that the highly purified
DNA binding domain of the VZV 140k transcriptional regulator
protein, is a stable dimer in solution and that it binds to DNA
as a dimer. Moreover, it readily heterodimerizes with the
corresponding domain of the HSV-1 IE protein, ICP4, suggesting
that the structures and sequences mediating dimerization are
conserved between these two homologous viral proteins.
Comparison of the sequences bound by the homo- and
heterodimeric proteins suggests that only one fully wild type
subunit of the dimer is sufficient for specific DNA recognition
in certain circumstances. Although the sequences required for
the DNA binding interaction of the alphaherpesvirus protein DNA
binding domains overlap with those required for the subunit
interaction, deletion and insertion mutations are less disruptive
to the later function.
Trie alphaherpesvirus regulatory proteins are closely related
and the primary structures of HSV-1 ICP4, HSV-2 ICP4, VZV
140k, PRV IE 180, EHV-1 IE1 and MDVICP4 have been divided
by extent of relative homology into five co-linear regions (24,
B.Barnett pers. comm., 1,48-50). Sequences spanning the
highly conserved region 2 of the HSV-1, VZV, and PRV protein
homologues have been found to encode a DNA binding domain
(29-32). These protein segments do not contain sequences that
obviously conform to any of the recognised classes of DNA
binding domain (51) and may well represent a novel class of DNA
binding structure.
Like its HSV-1 counterpart, the DNA binding domain of VZV
140k DNA has an intrinsic dimerization activity and binds to
DNA as a homodimer. We suggest that dimers of the 140k DNA
binding domain are highly stable and have a low rate of subunit
dissociation because: (a) no VT2 monomers were detected upon
gel filtration analysis of the purified VT2 peptide (Fig. 3), and
(b) heterodimer formation was not observed when the separately
translated DNA binding domain peptides were mixed together
(Figs. 4,5,6C,7C). The apparent high affinity of the monomer
units for each other suggests that dimerization of the 140k DNA
binding domain is likely to occur very rapidly after translation,
perhaps even concurrently with the polypeptide folding process,
as previously proposed for intact ICP4 (52).
Heterodimer formation between the VZV 140k and HSV-1
ICP4 DNA binding domain peptides occurred readily in vitro
(Fig. 4B). It is likely that equivalent protein-protein interactions
are involved in the formation of homodimers of the intact proteins
during their respective infections. The protein interface mediating
dimerization must be structurally similar in 140k and ICP4 to
allow heterodimerization, and it is possible that the actual
sequences involved in the interaction between monomers are
conserved or semi-conserved between these two regulatory
proteins.
The sizes of the mapped DNA binding domains of 140k and
ICP4 are very large compared to the established classes of DNA
binding domains, and it is likely that they contain distinct
sequences mediating their dimerization and DNA recognition
activities. In several of the defined classes of DNA binding
domain, the amino acid sequences involved in dimerization are
adjacent to the DNA recognition motif. Both the helix-loop-helix
class of proteins (for example MyoD) (53), and the leucine zipper
family of DNA binding proteins (for example GCN4) (54,55),
have a basic DNA recognition motif followed by an a-helical
region that provides a dimerization interface. Sequences strictly
conforming to these or other established types of multimerization
motifs are not found within the DNA binding domains of the
VZV 140k family of alphaherpesvirus proteins. Mapping the
sequences mediating DNA binding and dimerization requires the
identification of mutations that disrupt DNA binding but do not
affect dimerization; the insertion mutations in all but the most
peripheral sequences of HSV-1 ICP4 region 2 that we analyzed
were of this type. As no insertion mutations were identified that
disrupted dimerisation, it is possible that the ICP4 DNA binding
domain may be able to accommodate or compensate for the
effects of the insertions upon the individual facets of the
dimerization interface. Alternatively a short discrete sequence
that has not been affected by the insertions may mediate
dimerization. It is improbable that insertions il2 and il4 to il8
inclusive (into ICP4 sequences) are all directly disrupting DNA
binding, and it is more likely that the specific structure of the
domain required for DNA recognition is highly sensitive to minor
conformational alterations.
The fact that dimers containing the VZV 140k VT11 and VT12
peptides were detected, albeit at a low level, suggests that deletion
of the N-terminus of region 2 has indirect effects on the subunit
interaction. In agreement, sequences between 140k residues 472
and 525 were not sufficient for dimerization, as seen from gel
filtration analysis of a peptide comprising only these sequences
(data not shown). Sequences in the C-terminus of 140k region
2 (lacking from peptide VT8) are essential for dimerization. A
long tract of residues within these region 2 C-terminal sequences
is highly conserved (approximately 80% identity) between VZV
140k and HSV-1 ICP4, and secondary structure prediction
programmes suggest a highly a-helical nature of this tract. The
well studied helix-loop-helix (53) and leucine zipper (54)
dimerization motifs are almost totally a-helical, making the C-
terminal portion of region 2 of these alphaherpesvirus proteins
a particularly favourable candidate for mediating dimerization.
However, a single amino acid mutational analysis of these
conserved sequences in the ICP4 domain failed to identify any
substitutions that disrupted dimerization (K.E.Allen and
R.D.Everett, manuscript in preparation). It is possible that, as
with the 4 amino acid insertions, the dimerization activity of the
domain may tolerate minor changes of this type.
Heterodimers comprising VZV 140k peptide VT4X and a
severely DNA binding compromised mutant ICP4 peptide
(I10U2X) bind to DNA efficiently (Fig. 5). Additionally
140k/ICP4 DNA binding domain heterodimers bind to a probe
for which the ICP4 peptide homodimer has an extremely low
affinity (bottom panel of Fig. 5). These data suggest that only
one fully wild type subunit of the dimer is sufficient for the
specific interaction with the recognition site. This raises the
possibility that both subunits of the dimer are able to bind DNA
independently, however there is no evidence for this occurring;
gel retardation experiments using probes of different sizes in
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separate and mixed incubations gave no evidence of complexes
containing both probe molecules (data not shown). The
observation that in certain circumstances only one fully wild type
subunit is sufficient for DNA binding could be explained by
several (non mutually exclusive) models:
Only one subunit normally contacts the DNA binding site (Fig.
8A). The second monomer does not directly contribute to the
specificity or affinity of the DNA binding interaction but stabilises
the overall protein-DNA complex. Evidence suggests that both
half sites of the ICP4 consensus are specifically recognised by
the wild type homodimers (30,32,33,56). The lack of a direct
repeat or any obvious dyad symmetry in the bipartite ICP4
consensus presents some difficulties for a model where monomers
interact in an equivalent manner with each half of the binding
site. In B form DNA the two half sites of the ATCGTCnnnn-
YCGRC consensus (underlined) (34) are predicted to lie on the
same face of the helix and could in theory be specifically contacted
by a single monomer. In a similar scenario, the trimeric
Drosophila heat shock factor (HSF) can form stable protein —
DNA complexes in which only two of the three identical
monomers contact the DNA (57).
Binding of the first monomer facilitates binding of the second
monomer (Fig. 8B). The high affinity binding of the wild type
monomer allows cooperative binding of the second monomer by
reducing its energy requirement for DNA binding. In this case,
the low affinity of the mutant monomer would not significantly
reduce the DNA binding affinity of the heterodimer while the
mutant homodimer would fail to bind DNA. The recognition site
for the yeast GCN4 transactivator protein has non-equivalent half
sites: the GCN4 interaction with the left half site is strong
compared to the relatively weak right half site (58). The nature
of this binding site facilitates cooperative binding of the second
monomer of the GCN4 dimer to the weak half site, a similar
situation may hold for the ICP4 and 140k binding sites.
Dimerization with a wild type monomer induces a conformational
change in the mutant monomer (Fig. 8C). Binding to the wild
type monomer induces the mutant monomer to adopt a DNA
binding competent conformation either before or after binding
to DNA. In the presence of DNA, many DNA binding proteins
adopt stabilized structures, for example the X Cro protein
undergoes a large quaternary change when the dimer binds to
its operator sequence (59). Structural changes in the wild type
ICP4 monomer upon DNA binding may induce analogous
conformational changes in the mutant ICP4 subunit, restoring
its ability to specifically recognise target sequences.
However, heterodimers including a version of the ICP4 DNA
binding domain containing insertion mutation i 14, il5, il6, il7
or il8, failed to bind to DNA. If the outcome of these particular
insertion mutations is to induce a profound conformational change
on the domain, then it can be envisaged how the altered domain
structure could prevent or destabilize heterodimer-DNA
interactions occurring by any of the three models presented above.
The data presented here extends and confirms previous
observations on the relatedness of the HSV-1 ICP4 and VZV
140k proteins. The ability to obtain large amounts of functional
highly purified VZV 140k DNA binding domain from engineered
E.coli, as described here, should facilitate future structural
analyses and hopefully elucidate details of its dimerization and
DNA binding interactions.
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